## Drug of Choice for Uncomplicated Urogenital Gonorrhea **Key Point:** Ceftriaxone 250 mg IM as a single dose is the current gold-standard first-line treatment for uncomplicated N. gonorrhoeae infection, recommended by WHO, CDC, and Indian guidelines. ### Rationale for Ceftriaxone **High-Yield:** Ceftriaxone is preferred because: 1. **Efficacy**: Achieves >99% cure rates for urogenital, pharyngeal, and rectal gonorrhea 2. **Resistance profile**: Highly effective against penicillin-resistant N. gonorrhoeae (PRNG) and chromosomally resistant N. gonorrhoeae (CRNG) 3. **Single-dose convenience**: Improves compliance and reduces treatment failure 4. **Tissue penetration**: Excellent penetration into urethral, cervical, and other mucosal tissues ### Why Other Options Are Obsolete or Suboptimal | Drug | Status | Reason for Rejection | |------|--------|---------------------| | Penicillin G | **Obsolete** | Widespread resistance (PRNG/CRNG); cure rates <80%; no longer recommended | | Tetracycline | **Obsolete** | High resistance rates (>30%); poor efficacy; associated with treatment failure | | Fluoroquinolones | **No longer recommended** | Widespread resistance globally; WHO/CDC discontinued recommendations since 2007; high treatment failure rates | **Clinical Pearl:** The shift from penicillin → fluoroquinolones → cephalosporins mirrors the emergence of resistance patterns. Ceftriaxone remains the only reliable agent with sustained efficacy. **Warning:** Fluoroquinolone resistance in N. gonorrhoeae exceeds 50% in many regions, including India. Do not use for gonorrhea regardless of patient preference. ### Current Indian Guidelines Indian STI management protocols (NACO, AIIMS) recommend ceftriaxone 250 mg IM single dose as first-line for all forms of uncomplicated gonorrhea.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.